Old Web
English
Sign In
Acemap
>
authorDetail
>
Ulrike Kohlweyer
Ulrike Kohlweyer
University of Freiburg
Medicine
Physical therapy
Immunology
Bortezomib
Vorinostat
4
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)
2015
Blood
Alexander Keller
Johannes Waldschmidt
Dagmar Wider
Dorothee Jakobs
Mandy Möller
Heike Reinhardt
Milena Pantic
Olga Grishina
Gabriele Ihorst
Annette M. May
Anna V. Frey
Ulrike Kohlweyer
Justus Duyster
Manfred Jung
Monika Engelhardt
Ralph Wäsch
Show All
Source
Cite
Save
Citations (1)
Vorinostat (V), bortezomib (B), doxorubicin (Dox) and dexamethasone (Dex, VBDD) in relapsed or refractory multiple myeloma patients (pts): results of an open, non-comparative, phase I/II investigator initiated trial (IIT)
2015
Clinical Lymphoma, Myeloma & Leukemia
Alexander Keller
Johannes Waldschmidt
Dagmar Wider
Dorothee Jakobs
Mandy Möller
Heike Reinhardt
Milena Pantic
Olga Grishina
Gabriele Ihorst
Annette M. May
Anna V. Frey
Ulrike Kohlweyer
Manfred Jung
Justus Duyster
Ralph Wäsch
Monika Engelhardt
Show All
Source
Cite
Save
Citations (0)
The organization and support of clinical trials (CTs) in oncology patients through a center of clinical investigations, optimization, standardization, and safety (CIO) team.
2011
Journal of Clinical Oncology
Ulrike Kohlweyer
S. Rohdenburg
Heike Reinhardt
R. Zurheiden
V. Schmidt
Manuela Burbeck
Monika Engelhardt
Show All
Source
Cite
Save
Citations (0)
Correspondence (letter to the editor): Ordering errors were identified.
2010
Deutsches Arzteblatt International
Monika Engelhardt
Ulrike Kohlweyer
Martina Kleber
Show All
Source
Cite
Save
Citations (0)
1